Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Public ClinicalTrials.gov record NCT00696020. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL administered with 5 micrograms tiotropium bromide solution for inhalation, delivered by the Respimat inhaler, once daily for four weeks in patients with chronic obstructive pulmonary disease (COPD).
Study identification
- NCT ID
- NCT00696020
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 360 participants
Conditions and interventions
Conditions
Interventions
- BI 1744 CL/tiotropium bromide fixed dose combination Drug
- tiotropium bromide Drug
- Respimat® Inhaler Device
Drug · Device
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2008 (Type not available)
- Primary completion
- Feb 2009 (Actual)
- Completion
- Not listed
- Last update posted
- Aug 13, 2015
Started 2008
United States locations
- U.S. sites
- 22
- U.S. states
- 14
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1237.4.0118 Boehringer Ingelheim Investigational Site | Riverside | California | — | — |
| 1237.4.0103 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 1237.4.0115 Boehringer Ingelheim Investigational Site | Wheat Ridge | Colorado | — | — |
| 1237.4.0105 Boehringer Ingelheim Investigational Site | Clearwater | Florida | — | — |
| 1237.4.0110 Boehringer Ingelheim Investigational Site | DeLand | Florida | — | — |
| 1237.4.0117 Boehringer Ingelheim Investigational Site | Tampa | Florida | — | — |
| 1237.4.0104 Boehringer Ingelheim Investigational Site | Coeur d'Alene | Idaho | — | — |
| 1237.4.0120 Boehringer Ingelheim Investigational Site | Edina | Minnesota | — | — |
| 1237.4.0112 Boehringer Ingelheim Investigational Site | Minneapolis | Minnesota | — | — |
| 1237.4.0119 Boehringer Ingelheim Investigational Site | Saint Charles | Missouri | — | — |
| 1237.4.0114 Boehringer Ingelheim Investigational Site | Raleigh | North Carolina | — | — |
| 1237.4.0102 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
| 1237.4.0111 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 1237.4.0106 Boehringer Ingelheim Investigational Site | Spartanburg | South Carolina | — | — |
| 1237.4.0107 Boehringer Ingelheim Investigational Site | Spartanburg | South Carolina | — | — |
| 1237.4.0123 Boehringer Ingelheim Investigational Site | Knoxville | Tennessee | — | — |
| 1237.4.0122 Boehringer Ingelheim Investigational Site | Killeen | Texas | — | — |
| 1237.4.0109 Boehringer Ingelheim Investigational Site | New Braunfels | Texas | — | — |
| 1237.4.0108 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
| 1237.4.0116 Boehringer Ingelheim Investigational Site | Spokane | Washington | — | — |
| 1237.4.0121 Boehringer Ingelheim Investigational Site | Tacoma | Washington | — | — |
| 1237.4.0101 Boehringer Ingelheim Investigational Site | Morgantown | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00696020, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 13, 2015 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00696020 live on ClinicalTrials.gov.